| News

Polyneuron medication receives orphan drug status in the USA

11.06.2020

The American health authority has granted Polyneuron’s drug PN-1007 orphan designation. This status uses special conditions to balance out commercial disadvantages when developing drugs for rare diseases.

Ruben Herrendorff, CEO Polyneuron Pharmaceuticals

According to a press release, a drug manufactured by Polyneuron Pharmaceuticals AG based in Basel has received orphan drug status from the American health authority, the FDA. This status granted to medicines for use in rare diseases helps pharmaceutical companies to develop drugs for which there is only a very small niche market.

The drug developed by Polyneuron, called PN-1007, was developed to treat the autoimmune disease anti-MAG neuropathy. Over the course of the disease, the peripheral nerves become increasingly damaged, which can lead to physical impairments. There is currently no treatment with marketing authorization for this. PN-1007 neutralizes the autoantibodies responsible for this damage.

PN-1007 was already granted orphan drug status by the European Union back in 2017. Health authorities use this to encourage the development of such drugs through tax breaks and discounted fees, for instance in clinical testing. Additionally, research funds and long-term market exclusivity are guaranteed for ten years in the EU and for seven in the USA.

In a financing round in March this year, Polyneuron secured 22.5 million Swiss francs for its first clinical trial with this active substance.

Dr. Ruben Herrendorff, CEO and Co-Founder of Polyneuron, explains: “Receiving orphan designation in the U.S. provides additional validation to the development of PN-1007 as a treatment for anti-MAG neuropathy.” He goes on to add that data published recently in the Journal of Neurochemistry supports this. “We now look forward to evaluating PN-1007 in patients when our phase I/IIa study in anti-MAG neuropathy starts later in 2020.”

Polyneuron is headquartered at Technologiepark Basel. The company has also received support within the framework of BaseLaunch, the healthcare accelerator of the investment and innovation promotion agency Basel Area Business & Innovation.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Meteoblue constantly presents new developments
Basel Area Business & Innovation, Innovation, Invest

Meteoblue constantly presents new developments

The meteoblue weather service based in Basel has developed a weather map widget that can be embedded in any website....

Read More
Lonza manufactures coronavirus vaccine for Moderna
Basel Area Business & Innovation, Innovation, Invest

Lonza manufactures coronavirus vaccine for Moderna

Lonza plans to start production of Moderna’s coronavirus vaccine in Switzerland before the end of the year. Moderna published the...

Read More
Synendos raises 20 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Synendos raises 20 million Swiss francs

Synendos Therapeutics has concluded a Series A financing round, raising 20 million Swiss francs. The Basel biotech will use the...

Read More
Both Basel cantons are first class borrowers
Basel Area Business & Innovation, Invest

Both Basel cantons are first class borrowers

Standard & Poor’s has awarded the canton of Basel-City its top rating of AAA. The rating agency anticipates that Basel...

Read More
ChemAxon establishes subsidiary in Basel
Basel Area Business & Innovation, Innovation, Invest

ChemAxon establishes subsidiary in Basel

ChemAxon develops software for application in the chemicals and biopharma industries. Now, the Hungarian company has established a subsidiary in...

Read More
DSM strengthens the Basel Area life sciences cluster
Basel Area Business & Innovation, Innovation, Invest

DSM strengthens the Basel Area life sciences cluster

The global nutrition and health corporation Royal DSM is establishing a new innovation center at the headquarters of Nutritional Products...

Read More
1 2 3 37

Do you have a question? We'd like to hear from you.